ISRCTN57359805 https://doi.org/10.1186/ISRCTN57359805

# Phase I trial, Quotient Code: QSC300720

| | | |
|---|---|---|
| **Submission date**<br>14/07/2023 | **Recruitment status**<br>No longer recruiting | [X] Prospectively registered<br>[ ] Protocol<br>[ ] Statistical analysis plan<br>[ ] Results<br>[ ] Individual participant data<br>[ ] Record updated in last year |
| **Registration date**<br>19/07/2023 | **Overall study status**<br>Deferred | |
| **Last Edited**<br>19/07/2023 | **Condition category**<br>Other | |

**Plain English summary of protocol**
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

**Type(s)**
Principal investigator

**Contact name**
Dr Phil Evans

**Contact details**
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

**Type(s)**
Scientific

**Contact name**
Dr Phil Evans

**Contact details**
Quotient Sciences Limited
Mere Way
Ruddington Fields

Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 300 1000
recruitment@weneedyou.co.uk

### Type(s)
Public

### Contact name
Dr Phil Evans

### Contact details
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

## Additional identifiers

### Integrated Research Application System (IRAS)
1007785

## Study information

### Scientific Title
Phase I trial, Quotient Code: QSC300720 [The full scientific title will be published within 30 months after the end of the trial]

### Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required
Ethics approval required

### Ethics approval(s)
1. submitted 06/07/2023, London Surrey Borders REC (2nd Floor 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8057; Surreyborders.rec@hra.nhs.uk), ref: 23/LO/0521

2. submitted 06/07/2023, MHRA (10 South Colonnade, Canary Wharf, London , E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 58311/0001/001-0001

### Study design
One-part single-centre non-randomized open-label study

### Primary study design
Interventional

### Study type(s)
Other

### Health condition(s) or problem(s) studied
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Intervention Type
Drug

### Phase
Phase I

### Drug/device/biological/vaccine name(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Primary outcome(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Key secondary outcome(s))
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Completion date
16/02/2024

## Eligibility

### Key inclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Participant type(s)**
Healthy volunteer

**Healthy volunteers allowed**
No

**Age group**
Adult

**Sex**
All

**Key exclusion criteria**
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Date of first enrolment**
27/09/2023

**Date of final enrolment**
16/02/2024

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**Quotient Sciences Limited**
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS

# Sponsor information

**Organisation**
Veradermics Inc

# Funder(s)

**Funder type**
Industry

**Funder Name**
Veradermics Inc

# Results and Publications

**Individual participant data (IPD) sharing plan**
The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

**IPD sharing plan summary**
Not expected to be made available